This article focuses on the spin-off of biotech startup Viela Bio from AstraZeneca’s research and development arm MedImmune Inc. The coverage notes that Members Chris Jeffers and Elizabeth Parsons helped negotiate the deal along with AstraZeneca’s legal team. Chris and Elizabeth are quoted in the article discusses considerations that need to be made during spinouts such as this one.

Source

Baltimore Business Journal